Fig. 4

CMTM5 inhibits tumour growth and metastasis through regulating PI3K-AKT signalling. a The related proteins of PI3K/Akt pathway, including AKT, pAKT, PI3K p85 subunit, p21, cyclinD1, cyclinE, Bcl2, Bax, Bad, cleaved caspase 3, MMP2 and MMP9 in CMTM5 overexpressed Huh7 cells were examined by western blotting. b The relative kinase activity of PI3K in CMTM5 overexpressed Huh7 cells were examined by PI3K kinase ELISA assay. c The proteins levels of AKT, pAKT and P85 in Huh7-CMTM5 cells after treatment of PI3K inhibitor LY294002 (10 μM). d–g Huh7-CMTM5 cells were treated with or without LY294002, Cell growth (d), cell apoptosis (e) and cell metastatic and invasion (f, g) were examined. h–j The expression of PI3K p85 and pAKT (Ser473) in 76 paired tumour and adjacent normal liver tissues were examined by IHC staining and scored from 0 to 9 as described in the method. The left plots (h) were representative results of IHC staining against indicated proteins. The right plots were the statistical analysis of the correlation of CMTM5 expression with p85 (i) and pAKT (j) in HCC tissues (Spearman correlation test). Data are shown as mean ± SD from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, One-Way ANOVA with Dunnett’s test